BRUSSELS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced further data characterizing the clinical profile of dapirolizumab pegol (DZP), an investigational biologic for people living with systemic lupus erythematosus (SLE). The data are being presented across five posters at ACR Convergence 2026, the…
BRUSSELS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced further data characterizing the clinical profile of dapirolizumab pegol (DZP), an investigational biologic for people living with systemic lupus erythematosus (SLE). The data are being presented across five posters at ACR Convergence 2026, the annual meeting of the American College of Rheumatology, in Orlando, Florida, November 6-11.
The Company has expanded its AI-powered quantum error correction program across three IBM quantum processors, building on its earlier work using datasets generated by Google quantum hardware and advancing its hardware-agnostic decoding technology.
Sabrina Martucci Johnson, Founder, President and CEO, discusses numerous potential value drivers expected to power the Company’s next phase of growth and commercial success
Related Bing News Results Globe Newswire, World News and Updates | Toronto Sun Mon, 09 Nov 2026 00:02:00 GMT SINGAPORE, Nov. 06, 2026 (GLOBE NEWSWIRE) — BitFuFu Inc. (“BitFuFu” or the “Company”) (NASDAQ: FUFU), a world-leading Bitcoin miner and mining services innovator, today announced its unaudited Bitcoin ...
